CORCEPT THERAPEUTICS INCORPORATED - COMMON STOCK

Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing’s Syndrome

01 Apr 2024 05:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update

15 Feb 2024 13:07:00 By Nasdaq GlobeNewswire

Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial

15 Feb 2024 13:02:00 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results, Provide Corporate Update and Host Conference Call

08 Feb 2024 13:05:00 By Nasdaq GlobeNewswire

Corcept Appoints Roberto Vieira as President, Oncology

29 Jan 2024 05:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Provides Financial Update and Announces Stock Repurchase Program

08 Jan 2024 05:00:01 By Nasdaq GlobeNewswire

Court Finds Corcept Therapeutics’ Patents Not Infringed

02 Jan 2024 05:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update

01 Nov 2023 13:05:00 By Nasdaq GlobeNewswire

Corcept Appoints Monica Tellado as President, Emerging Markets

01 Nov 2023 05:00:00 By Nasdaq GlobeNewswire

Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)

26 Oct 2023 13:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

25 Oct 2023 13:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

02 Aug 2023 13:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

26 Jul 2023 13:05:00 By Nasdaq GlobeNewswire

Corcept’s Miricorilant Shows Great Promise in Treatment of Non-Alcoholic Steatohepatitis (NASH)

17 Jul 2023 13:05:00 By Nasdaq GlobeNewswire

Journal of Clinical Oncology Publishes Results of Corcept’s Phase 2 Trial of Relacorilant in Women With Platinum-Resistant Ovarian Cancer

27 Jun 2023 05:00:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update

03 May 2023 13:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call

26 Apr 2023 13:05:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Final Results of Tender Offer

05 Apr 2023 13:05:00 By Nasdaq GlobeNewswire

Corcept Therapeutics Announces Preliminary Results of Tender Offer

03 Apr 2023 05:00:01 By Nasdaq GlobeNewswire

Corcept Therapeutics Initiates CATALYST Clinical Trial

28 Mar 2023 13:05:00 By Nasdaq GlobeNewswire